Navigation Links
EpiVax Research on Tregitopes Wins 2010 AAPS Innovation in Biotechnology Award
Date:5/25/2010

co-administration of Tregitopes with a wide range of proteins (such as FVIII, thyroid stimulating hormone receptor, ovalbumin, and autoantigens) leads to suppression of T cell and antibody responses to test antigens.

About EpiVax
EpiVax, Inc. is a privately held company based in Providence, Rhode Island. EpiVax uses cutting edge bioinformatics tools (more specifically, immunoinformatics tools such as the EpiMatrix algorithm) to improve the efficacy and safety of vaccines and biologic products (proteins such as Humira, Factor VIII, and Botox). EpiVax’ also has extensive internal programs focused on developing new methods for modulating the human immune response using its Tregitope Technology platform. For more information about EpiVax, please visit www.epivax.com. For more information on the Tregitope technology and EpiVax’ other offerings please contact Jason Del Pozzo at jdelpozzo(at)epivax(dot)com.

###

Read the full story at http://www.prweb.com/releases/2010/05/prweb4043544.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Page: 1 2 3

Related biology technology :

1. EpiVax, Inc. forms Collaborative Research Agreement with Roche to Develop Tregitope Technology
2. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
5. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
6. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
7. eResearchTechnology to Present at the Thomas Weisel Healthcare Conference 2007 on September 5th
8. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
9. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
10. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
11. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
EpiVax Research on Tregitopes Wins 2010 AAPS Innovation in Biotechnology Award
(Date:12/22/2014)... , Dec. 22, 2014   Synthetic ... developer of pathogen-specific therapies for serious infections ... the microbiome, today announced positive topline safety ... clinical trial of SYN-004, the Company,s investigational ... Clostridium difficile (C. difficile) infection, ...
(Date:12/22/2014)... 2014  Alternative Energy & Environmental Solutions, Inc., ... a letter of intent to acquire BioTechPharma Corporation, ... a nanotechnology-based development platform used to create drug ... on-site collection and testing to identify infectious disease, ... an immediate, non-invasive and cost-effective manner. ...
(Date:12/22/2014)...  ( www.competitivehealth.com ) — Competitive Health is pleased ... and advocacy service, has signed an agreement to become ... health services marketplace. 63% of Americans have ... expected to pay. As part of an ongoing effort ... is pleased to offer medical bill review and negotiation ...
(Date:12/22/2014)... 22, 2014 ITRA Global, one of ... of commercial real estate, has further expanded its global ... Perth and Brisbane, Western Australia, reports Mylinda Vick, CCIM, ... ITRA Global / ACORPP (Australian Corporate Property and ... company providing property services to a wide range of ...
Breaking Biology Technology:Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5ALNE Announces Intention To Acquire BioTechPharma 2WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2ITRA Global Continues International Expansion in Perth and Brisbane, Australia 2
... Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL ), a specialty ... full year 2010 on Thursday, February 10, 2011 before the ... conduct a conference call that day at 10:00 a.m. ET ... full year 2010.  The presentation slides to be used during ...
... Biotechnology and Biomedicine and the UAB Department of Biochemistry ... using Saccharomyces cerevisiae yeast to detect in ... of molecules which can initiate the assembly of amyloid ... the efficacy of compounds which could dissolve or inhibit ...
... Calif., Feb. 2, 2011 Sangamo BioSciences, Inc. (Nasdaq: ... 2010 financial results and accomplishments. For the ... net loss of $8.3 million, or $0.18 per share, compared ... share, for the same period in 2009. As of December ...
Cached Biology Technology:Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 2011 2Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 2011 3Auxilium Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Results and Conduct Conference Call on Thursday, February 10, 2011 4New test to study proteins involved in neurodegenerative diseases 2Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results 2Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results 3Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results 4Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results 5Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results 6Sangamo BioSciences Reports Fourth Quarter and Full Year 2010 Financial Results 7
(Date:12/17/2014)... , Dec. 15, 2014 The Defense ... it easier to detect and prevent counterfeit microcircuits ... Today the agency started performing an in-house microcircuit ... validate the authenticity of purchased microcircuits while increasing ... quality control measures will be conducted at DLA,s ...
(Date:12/17/2014)... 2014  Automation is fundamentally transforming the travel ... at international borders. Over the past decade, ePassports, ... veteran travelers to self process through border control ... at an increasing number of airports, seaports, and ... According to Maxine Most , Principal at ...
(Date:12/11/2014)... 2014  That blood pressure plays a role in human ... the medical term for high blood pressure – was first ... inflatable cuff that,s used in measuring blood pressure was invented ... new about hypertension, its triggers and its effects. In fact, ... and the best ways to treat it. For ...
Breaking Biology News(10 mins):Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 2Defense Logistics Agency Launches DNA Marking Capability to Strengthen Microcircuit Supply Chain 3Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4
... common form of lung cancer may begin in a group ... the Howard Hughes Medical Institute. , Working in a mouse ... that can divide into fresh copies of itself and into ... lung. Their experiments show that at the earliest stage of ...
... suggests that medications commonly referred to as fertility drugs ... called the estrogen receptor beta. The study showed that ... that were genetically engineered to lack estrogen receptor beta. ... receptor proteins which mediate the effects of estrogen hormones ...
... In the human brain, cells talk to one another ... people fall into a deep sleep, the higher regions ... are a bustling grid of neural dialogue - apparently ... fade. , Writing today (Sept. 30) in the journal ...
Cached Biology News:Most common lung cancers may begin in newly discovered cells 2Most common lung cancers may begin in newly discovered cells 3Most common lung cancers may begin in newly discovered cells 4New Discovery May Help Doctors Treat Infertility 2New Discovery May Help Doctors Treat Infertility 3Deep sleep short-circuits brain's grid of connectivity 2Deep sleep short-circuits brain's grid of connectivity 3